Status:
COMPLETED
Auditive and Renal Long Term Outcomes - Risk After Aminoglycoside Therapy in Neonates (AURORA)
Lead Sponsor:
University Hospital of North Norway
Conditions:
Hearing Loss
Gentamicin Adverse Reaction
Eligibility:
All Genders
5-15 years
Brief Summary
Gentamicin, in combination with a beta-lactam antibiotic, is commonly used for treatment of neonatal sepsis. Neonates have a high volume of distribution. It is a paradox that most neonatal dosing sche...
Eligibility Criteria
Inclusion
- Exposed to gentamicin therapy in the neonatal period and treated at neonatal unit at the University Hospital of North Norway
Exclusion
- Not able to cooperate during an audiometry
Key Trial Info
Start Date :
September 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 15 2018
Estimated Enrollment :
226 Patients enrolled
Trial Details
Trial ID
NCT03253614
Start Date
September 15 2017
End Date
September 15 2018
Last Update
March 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of North Norway
Tromsø, Norway, N-9038